Proteostasis Therapeutics Licenses GeneGo's MetaCore | GenomeWeb

NEW YORK (GenomeWeb News) –GeneGo said today that Proteostasis Therapeutics has licensed its MetaCore curated data mining and analysis platform.

Proteostasis Therapeutics is developing small molecule therapeutics based on studies of the human proteostasis network, the balance of proteins that can protect the body from diseases, GeneGo said. Deficiencies in that network can lead to a range of diseases, such as emphysema, type II diabetes, Alzheimer's disease, and Huntington's disease, said GeneGo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.